Document And Entity Information
Document And Entity Information - shares | 3 Months Ended | |
Mar. 31, 2020 | May 13, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | VIVEVE MEDICAL, INC. | |
Entity Central Index Key | 0000879682 | |
Trading Symbol | vive | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 15,091,577 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Title of 12(b) Security | Common Stock |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 | [1] |
Current assets: | |||
Cash and cash equivalents | $ 9,042,000 | $ 13,308,000 | |
Accounts receivable, net of allowance for doubtful accounts of $481 and $407 as of March 31, 2020 and December 31, 2019, respectively | 1,279,000 | 1,573,000 | |
Inventory | 4,459,000 | 4,861,000 | |
Prepaid expenses and other current assets | 2,204,000 | 2,447,000 | |
Total current assets | 16,984,000 | 22,189,000 | |
Property and equipment, net | 2,973,000 | 3,046,000 | |
Investment in limited liability company | 1,034,000 | 1,216,000 | |
Other assets | 441,000 | 526,000 | |
Total assets | 21,432,000 | 26,977,000 | |
Current liabilities: | |||
Accounts payable | 2,262,000 | 1,608,000 | |
Accrued liabilities | 2,323,000 | 4,698,000 | |
Total current liabilities | 4,585,000 | 6,306,000 | |
Note payable, noncurrent portion | 4,110,000 | 3,983,000 | |
Other noncurrent liabilities | 186,000 | 167,000 | |
Total liabilities | 8,881,000 | 10,456,000 | |
Commitments and contingences (Note 8) | |||
Stockholders’ equity: | |||
Common stock, $0.0001 par value; 75,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 10,028,203 and 7,075,684 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively | 1,000 | 1,000 | |
Additional paid-in capital | 216,771,000 | 214,431,000 | |
Accumulated deficit | (204,221,000) | (197,911,000) | |
Total stockholders’ equity | 12,551,000 | 16,521,000 | |
Total liabilities and stockholders’ equity | 21,432,000 | 26,977,000 | |
Series A Preferred Stock [Member] | |||
Stockholders’ equity: | |||
Convertible preferred stock | |||
Series B Preferred Stock [Member] | |||
Stockholders’ equity: | |||
Convertible preferred stock | |||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | [1] |
Accounts receivable, allowance for doubtful accounts | $ 481 | $ 407 | |
Convertible preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 | |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Common stock, shares authorized (in shares) | 75,000,000 | 75,000,000 | |
Common stock, shares issued (in shares) | 10,028,203 | 7,075,684 | |
Common stock, shares outstanding (in shares) | 10,028,203 | 7,075,684 | |
Series A Preferred Stock [Member] | |||
Convertible preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Convertible preferred stock, shares issued (in shares) | 0 | 1,852,173 | |
Convertible preferred stock, shares outstanding (in shares) | 0 | 1,852,173 | |
Series B Preferred Stock [Member] | |||
Convertible preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Convertible preferred stock, shares issued (in shares) | 32,667 | 31,678 | |
Convertible preferred stock, shares outstanding (in shares) | 32,667 | 31,678 | |
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Revenue | $ 1,304,000 | $ 3,012,000 |
Cost of revenue | 1,129,000 | 1,941,000 |
Gross profit | 175,000 | 1,071,000 |
Operating expenses: | ||
Research and development | 1,637,000 | 2,480,000 |
Selling, general and administrative | 4,365,000 | 6,626,000 |
Restructuring costs | 742,000 | |
Total operating expenses | 6,002,000 | 9,848,000 |
Loss from operations | (5,827,000) | (8,777,000) |
Interest expense, net | (210,000) | (1,116,000) |
Other expense, net | (91,000) | (11,000) |
Net loss from consolidated companies | (6,128,000) | (9,904,000) |
Loss from minority interest in limited liability company | (182,000) | (125,000) |
Comprehensive and net loss | (6,310,000) | (10,029,000) |
Series B convertible preferred stock dividends | (989,000) | |
Net loss attributable to common stockholders | $ (7,299,000) | $ (10,029,000) |
Net loss per share of common stock: | ||
Basic and diluted (in dollars per share) | $ (0.82) | $ (21.63) |
Weighted average shares used in computing net loss per common share: | ||
Basic and diluted (in shares) | 8,930,744 | 463,719 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands | November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | November 2019 Offering [Member]Common Stock [Member] | November 2019 Offering [Member]Additional Paid-in Capital [Member] | November 2019 Offering [Member]Retained Earnings [Member] | November 2019 Offering [Member] | Series A Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Series A Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series A Warrants [Member]Common Stock [Member] | Series A Warrants [Member]Additional Paid-in Capital [Member] | Series A Warrants [Member]Retained Earnings [Member] | Series A Warrants [Member] | Series B Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Series B Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series B Warrants [Member]Common Stock [Member] | Series B Warrants [Member]Additional Paid-in Capital [Member] | Series B Warrants [Member]Retained Earnings [Member] | Series B Warrants [Member] | Preferred Stock [Member]Series A Preferred Stock [Member] | Preferred Stock [Member]Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Series B Preferred Stock [Member] | Total | |
Balances (in shares) at Dec. 31, 2018 | 463,630 | |||||||||||||||||||||||||
Balances at Dec. 31, 2018 | $ 160,297 | $ (155,385) | $ 4,912 | |||||||||||||||||||||||
Stock-based compensation expense | 470 | 470 | ||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 429 | |||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 35 | 35 | ||||||||||||||||||||||||
Issuance of restricted shares (in shares) | 6 | |||||||||||||||||||||||||
Issuance of restricted shares | 1 | 1 | ||||||||||||||||||||||||
Net loss | (10,029) | (10,029) | ||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement (in shares) | 274 | |||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement | 25 | 25 | ||||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2019 | 464,339 | |||||||||||||||||||||||||
Balances at Mar. 31, 2019 | 160,828 | (165,414) | (4,586) | |||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2018 | 463,630 | |||||||||||||||||||||||||
Balances at Dec. 31, 2018 | 160,297 | (155,385) | 4,912 | |||||||||||||||||||||||
Series B convertible preferred stock dividends (in shares) | 378 | |||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2019 | 1,852,173 | 31,678 | 7,075,684 | |||||||||||||||||||||||
Balances at Dec. 31, 2019 | $ 1 | 214,431 | (197,911) | 16,521 | [1] | |||||||||||||||||||||
Issuance costs in connection with November 2019 Offering | $ (30) | $ (30) | ||||||||||||||||||||||||
Conversion of Series A convertible preferred stock into common stock (in shares) | (1,852,173) | |||||||||||||||||||||||||
Conversion of Series A convertible preferred stock into common stock | ||||||||||||||||||||||||||
Conversion of Series A convertible preferred stock into common stock (in shares) | 1,852,173 | |||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises (in shares) | 1,026,240 | 45,473 | ||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises | $ 1,591 | $ 1,591 | $ 70 | $ 70 | ||||||||||||||||||||||
Series B convertible preferred stock dividends (in shares) | 989 | 989 | ||||||||||||||||||||||||
Series B convertible preferred stock dividends | (1) | (1) | ||||||||||||||||||||||||
Stock-based compensation expense | 686 | 686 | ||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 320 | |||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | ||||||||||||||||||||||||||
Issuance of restricted shares (in shares) | 28,313 | |||||||||||||||||||||||||
Issuance of restricted shares | 24 | 24 | ||||||||||||||||||||||||
Net loss | (6,310) | (6,310) | ||||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2020 | 32,667 | 10,028,203 | ||||||||||||||||||||||||
Balances at Mar. 31, 2020 | $ 1 | $ 216,771 | $ (204,221) | $ 12,551 | ||||||||||||||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Cash flows from operating activities: | |||
Net loss | $ (6,310,000) | $ (10,029,000) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Provision for doubtful accounts | 74,000 | 111,000 | |
Depreciation and amortization | 323,000 | 311,000 | |
Stock-based compensation | 710,000 | 496,000 | |
Non-cash interest expense | 127,000 | 399,000 | |
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities | 5,000 | 10,000 | |
Loss from minority interest in limited liability company | 182,000 | 125,000 | |
Changes in assets and liabilities: | |||
Accounts receivable | 220,000 | 815,000 | |
Inventory | 313,000 | 206,000 | |
Prepaid expenses and other current assets | 243,000 | (559,000) | |
Other noncurrent assets | 417,000 | 17,000 | |
Accounts payable | 654,000 | (1,310,000) | |
Accrued and other liabilities | (2,654,000) | (2,202,000) | |
Other noncurrent liabilities | (40,000) | 52,000 | |
Net cash used in operating activities | (5,736,000) | (11,558,000) | |
Cash flows from investing activities: | |||
Purchase of property and equipment | (161,000) | (179,000) | |
Net cash used in investing activities | (161,000) | (179,000) | |
Cash flows from financing activities: | |||
Transaction costs in connection with November 2019 Offering | (30,000) | ||
Proceeds from exercise of Series A and B common warrants | 1,661,000 | ||
Proceeds from issuance of common shares from employee stock purchase plan | 35,000 | ||
Net cash provided by financing activities | 1,631,000 | 35,000 | |
Net decrease in cash and cash equivalents | (4,266,000) | (11,702,000) | |
Cash and cash equivalents - beginning of period | 13,308,000 | [1] | 29,523,000 |
Cash and cash equivalents - end of period | 9,042,000 | 17,821,000 | |
Supplemental disclosure: | |||
Cash paid for interest | 675,000 | ||
Cash paid for income taxes | |||
Supplemental disclosure of cash flow information as of end of period: | |||
Issuance of Series B convertible preferred stock in settlement of dividends | 989,000 | ||
Issuance of note payable in settlement of accrued interest | 126,000 | 318,000 | |
Net transfer of equipment between inventory and property and equipment | 89,000 | 46,000 | |
Operating cash outflows from operating leases | 75,000 | 73,000 | |
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842) | $ 629,000 | ||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 1 - The Company and Basis
Note 1 - The Company and Basis of Presentation | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 In November December 2019, 600,000 3,021,237 January February 2020, 1,183,151 669,022 March 31, 2020, no In February 2020, 1,026,240 $1,591,000. February 2020, 45,473 $70,000. March 31, 2020, 6,393,113 7,373,800 In connection with the closing of the November 2019 $28,981,000 $31,300,000, 31,300 9,893,776 6 5 120% $1.53 $1.836 one ATM Equity Offerings The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, August 16, 2019, may $6,760,000 “August 2019 $6,760,000 August 2019 September 2019. December 31, 2019, 1,004,171 August 2019 $6,322,000. three March 31, 2020 2019, zero November 2017 March 31, 2020, no August 2019 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2019, March 19, 2020. three March 31, 2020 not December 31, 2020 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of March 31, 2020, $204,221,000, $9,042,000 $12,399,000. $5,736,000 three March 31, 2020. May 2021. not one To fund further operations, the Company will need to raise additional capital. The Company may no not no no |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2020, one 48% three March 31, 2019, three 42% There were no 10% three March 31, 2020 2019. As of March 31, 2020, two 49% December 31, 2019, two 49% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $481,000 March 31, 2020 $407,000 December 31, 2019. There were no three March 31, 2020 2019. Revenue from Contracts with Cus t omers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of six nine June 30, 2019 not March 31, 2020 December 31, 2019, $703,000 $662,000, three March 31, 2020, $297,000 December 31, 2019. In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2020 December 31, 2019. $25,000 $108,000, not March 31, 2020 December 31, 2019, three March 31, 2020, $83,000 December 31, 2019. The following table reflects the changes in our customer contract liabilities for the three March 31, 2020: March 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 25 $ 108 $ (83 ) Total $ 25 $ 108 $ (83 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2020 2019, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $211,000 $337,000 March 31, 2020 December 31, 2019, June 30, 2019 no three March 31, 2019. three March 31, 2020 2019, $198,000 no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 North America $ 688 $ 1,792 Asia Pacific 597 967 Europe and Middle East 5 246 Latin America 14 - Other - 7 Total $ 1,304 $ 3,012 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2020 2019. Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2020 2019, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Three Months Ended March 31, 2020 2019 Series B convertible preferred stock 32,667 (a) - Warrants to purchase common stock 23,665,905 6,408 Stock options to purchase common stock 10,432,654 55,864 Restricted common stock awards 2,620 4,176 (a) Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1 653.59 $1,000 $1.53 not Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not not no We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no March 31, 2020 December 31, 2019. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 31, 2020, December 31, 2019 There were no |
Note 4 - Investment in Limited
Note 4 - Investment in Limited Liability Company | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not three March 31, 2020 2019, 120 300 $10,000 $27,000, March 31, 2020, 4,920 $10,000 $27,000 three March 31, 2020 2019, no March 31, 2020 December 31, 2019. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not March 31, 2020, 7% three three March 31, 2020 2019, $182,000 $125,000, In February 2019, no |
Note 5 - Accrued Liabilities
Note 5 - Accrued Liabilities | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 5. Accrued Liabilities Accrued liabilities consisted of the following as of March 31, 2020 December 31, 2019 ( March 31, December 31, 2020 2019 Accrued payroll and other related expenses $ 719 $ 839 Deferred revenue - subscription rental program 703 662 Current operating lease liabilities 278 268 Accrued professional fees 224 592 Accrued bonuses 215 726 Accrued sales commission 60 281 Accrued inventory - 474 Accrued interest - 440 Other accruals 124 416 Total accrued liabilities $ 2,323 $ 4,698 |
Note 6 - Note Payable
Note 6 - Note Payable | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 6. Note Payable On May 22, 2017, December 12, 2017 November 29,2018 “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may In connection with the 2017 two 10 2,220 $950.00 10 Under the 2017 November 12, 2019 six four 2017 12.5%, 4.0% may, three March 31, 2019, $318,000 5.0% As security for its obligations under the 2017 The terms of the 2017 $2,000,000 2022, not 2.0 2017 On November 12, 2019, 2017 No. 3” $28,981,000 $31,300,000. 31,300 9,893,776 5 120% $1.53 $1.836 9 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company’s ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. During the three March 31, 2020, $126,000 As of March 31, 2020, As of March 31, 2020 December 31, 2019, $4,110,000 $3,983,000, The Company accounted for the changes in the 2017 31,300 9,893,776 November 26, 2019 1 $0.869 November 26, 2019); ( 2 73%; 3 2 4 1.58%. $1,023.23 $32,027,000. $3,502,000 10 $6,705,000, December 31, 2019. As of March 31, 2020, Year Ending December 31, 2020 (remaining 9 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,871 ) Present value of obligations 4,121 Less: Unamortized debt discount (11 ) Note payable, noncurrent portion $ 4,110 |
Note 7 - Leases
Note 7 - Leases | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 7. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2021. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at March 31, 2020 December 31, 2019 ( March 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 332 $ 395 Liabilities: Current operating lease liabilities $ 278 $ 268 Noncurrent operating lease liabilities 59 132 $ 337 $ 400 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the three March 31, 2020 2019 $76,000 $75,000, As of March 31, 2020, Year Ending December 31, 2020 (remaining 9 months) $ 228 2021 137 Total lease payments 365 Less: Amount representing interest (28 ) Present value of lease liabilities $ 337 The weighted average remaining lease term was approximately 14 March 31, 2020. three March 31, 2020 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of March 31, 2020 , Year Ending December 31, 2020 (remaining 9 months) $ 660 2021 43 Thereafter - Total $ 703 As of March 31, 2020, $1,163,000 three March 31, 2020 $113,000. |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 8. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not |
Note 9 - Preferred Stock
Note 9 - Preferred Stock | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 9. Preferred Stock In connection with the closing of the public offering in November 2019, With certain exceptions, as described in the Series A Certificate of Designation, the shares of Series A preferred stock have no Each share of Series A convertible preferred stock is convertible at any time at the holder’s option into one In November December 2019, 600,000 3,021,237 January February 2020, 1,183,151 669,022 March 31, 2020, no As previously reported (see Note 6 31,300 9,893,776 November 26, 2019, 12.5% December 31, 2019, 378 $2,400 three March 31, 2020, 989 $1,000 March 31, 2020, 32,667 no The Series B convertible preferred stock provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company’s organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. The fair value of the Series B convertible preferred stock was determined in connection with the CRG debt conversion as part of the accounting for that transaction as a troubled debt restructuring. (See Note 6 November 26, 2019, $1,023.23 $32,027,000 31,300 Under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not |
Note 10 - Common Stock
Note 10 - Common Stock | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 10. Common Stock In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $1.55 one one $1.55 first one $1.55 fifth 2 $1.55 one one one $1.55 first one $1.55 fifth The securities comprising the units were immediately separable and were issued separately. A total of 1,945,943 5,473,410 7,419,353 7,419,353 In November December 2019, 600,000 3,021,237 January February 2020, 1,183,151 669,022 In February 2020, 1,026,240 $1,591,000. In February 2020, 45,473 $70,000. ATM Equity Offerings Through the August 2019 may $6,760,000 $6,760,000 August 2019 September 2019. three September 30, 2019, 1,004,171 August 2019 $6,322,000. Restricted Common Shares In March 2020, 28,313 $24,000. In December 2019, 30,675 $25,000. In October 2019, 7,740 $25,000. In March 2019, 274 $25,000. Warrants for Common Stock As of March 31, 2020, Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 1.55 6,393,113 November 2019 Common Shares November 26, 2024 $ 1.55 7,373,880 November 2019 Common Shares November 26, 2024 $ 1.84 9,893,776 23,665,905 In connection with the November 2019 7,419,353 7,419,353 one $1.55 first one $1.55 fifth one one $1.55 one five $1.55 $1,210,000 0%, 91.1%, 1.59% one $2,871,000 0%, 68.8%, 1.58% five $4,081,000 November 2019 In February 2020, 1,026,240 $1,591,000. February 2020, 45,473 $70,000. March 31, 2020, 6,393,113 7,373,800 In connection with the CRG Debt Conversion, CRG received warrants exercisable for 9,893,776 15% November 2019 five 120% $1.53 $1.836 $3,502,000 0%, 68.8%, 1.58% five In connection with the 2017 2,220, $950.00 ten $940,000 0%, 55.1%, 2.25% ten $790,000, three March 31, 2020 2019, $1,000 $83,000, March 31, 2020, $11,000. No three March 31, 2020 2019. No three March 31, 2020 2019. The stock-based compensation expense related to warrants issued was zero three March 31, 2020 2019, no |
Note 11 - Summary of Stock Opti
Note 11 - Summary of Stock Options | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 1 1 . Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of March 31, 2020, 2006 104 no $992.00 2.8 As of March 31, 2020, 2013 10,432,550 4,093,287 $1.94 9.7 In January 2020, 2020 2013 2,639,926 11,872,531 14,512,457 January 1, 2020. Activity under the 2006 2013 Three Months Ended March 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 468,000 $ 0.88 Options exercised - Options canceled (123,024 ) $ 20.25 Options outstanding, end of period 10,432,654 $ 1.95 9.7 $ - Vested and exercisable and expected to vest, end of period 9,404,561 $ 2.04 9.7 $ - Vested and exercisable, end of period 833,785 $ 9.63 9.6 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of March 31, 2020. The options outstanding and exercisable as of March 31, 2020 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2020 Price Term (Years) March 31, 2020 Price $0.69 - $0.89 10,238,979 $ 0.86 9.7 813,153 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.9 - $ - $38.00 - $58.00 1,600 $ 55.81 9.2 - $ - $100.00 - $197.00 20,352 $ 141.85 8.6 9,174 $ 147.74 $202.00 - $283.00 743 $ 251.21 7.6 392 $ 254.90 $311.00 - $382.00 2,625 $ 344.68 8.4 1,238 $ 345.28 $430.00 - $497.00 6,707 $ 454.33 7.3 4,281 $ 455.78 $501.00 - $567.00 3,215 $ 537.49 7.1 2,432 $ 536.76 $600.00 - $661.00 1,392 $ 602.19 5.8 1,375 $ 601.46 $700.00 - $792.00 1,937 $ 767.72 6.6 1,636 $ 767.47 $992.00 - $992.00 104 $ 992.00 2.8 104 $ 992.00 Total: 10,432,654 $ 1.95 9.7 833,785 $ 9.63 Restricted Stock Awards During the three March 31, 2020, no 2013 In July 2019, 378 2013 $38.08 378 In June 2019, 250 June 2018. In April 2019, 525 2013 $91.00 525 In January 2019, 3,625 2013 2018 2018 50% 50% three March 31, 2020, zero March 31, 2020, zero As of March 31, 2020, 2,620 2017 The tenth 2017 “2017 January 1, 2020 March 31, 2020, 320 March 31, 2020 $0.59. The ninth 2017 October 1, 2019 December 31, 2019, 300 December 31, 2019 $1.07. The eighth 2017 July 1, 2019 September 30, 2019, 200 September 30, 2019 $3.75. The seventh 2017 April 1, 2019 June 30, 2019, 602 June 28, 2019 $32.30. The sixth 2017 January 1, 2019 March 31, 2019, 429 March 29, 2019 $79.88. As of March 31, 2020, 2017 772 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended March 31, 2020 2019 Expected term (in years) 0.25 0.25 Average volatility 124% 74% Risk-free interest rate 1.54% 2.45% Dividend yield 0% 0% The weighted average grant date fair value of the purchase rights issued under the 2017 three March 31, 2020 2019 $0.43 $33.00, Stock-Based Compensation During the three March 31, 2020 2019, 368,000 21,175 $0.75 $123.66 no three March 31, 2020 2019. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 0.45% 2.53% Dividend yield 0% 0% During the three March 31, 2020 2019, 100,000 275 $1.36 $121.82 no three March 31, 2020 2019. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 1.39% 2.49% Dividend yield 0% 0% Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 Cost of revenue $ 60 $ 32 Research and development 87 40 Selling, general and administrative 564 424 Total 710 $ 496 As of March 31, 2020, $7,341,000. 3.1 |
Note 12 - Income Taxes
Note 12 - Income Taxes | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 1 2 . Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three March 31, 2020. 2020 0%. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 |
Note 13 - Related Party Transac
Note 13 - Related Party Transactions | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 1 3 . Related Party Transactions In June 2006, October 4, 2007. 300 March 31, 2020, 855 375 $282,000 $1,489,000 three March 31, 2020 2019, March 31, 2020 December 31, 2019 $323,000 $124,000, In August 2017, February 2019, no |
Note 14 - Restructuring Costs
Note 14 - Restructuring Costs | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Restructuring and Related Activities Disclosure [Text Block] | 1 4 . Restructuring Costs In January 2019, 40 $742,000 first 2019 |
Note 15 - Subsequent Events
Note 15 - Subsequent Events | 3 Months Ended |
Mar. 31, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 1 5 . Subsequent Events On April 24, 2020, $1,343,400 1.00% two seven may No On April 15, 2020, $1.55 $0.61 April 16, 2020, 4,820,584 242,790 $3.1 2 4,820,584 2 242,790 $0.6371 five April 20, 2020. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. |
Reserve Stock Split, Policy [Policy Text Block] | Reverse Stock Split The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2020, one 48% three March 31, 2019, three 42% There were no 10% three March 31, 2020 2019. As of March 31, 2020, two 49% December 31, 2019, two 49% |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $481,000 March 31, 2020 $407,000 December 31, 2019. There were no three March 31, 2020 2019. |
Revenue from Contract with Customer [Policy Text Block] | Revenue from Contracts with Cus t omers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System generally have a rental period of six nine June 30, 2019 not March 31, 2020 December 31, 2019, $703,000 $662,000, three March 31, 2020, $297,000 December 31, 2019. In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2020 December 31, 2019. $25,000 $108,000, not March 31, 2020 December 31, 2019, three March 31, 2020, $83,000 December 31, 2019. The following table reflects the changes in our customer contract liabilities for the three March 31, 2020: March 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 25 $ 108 $ (83 ) Total $ 25 $ 108 $ (83 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2020 2019, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $211,000 $337,000 March 31, 2020 December 31, 2019, June 30, 2019 no three March 31, 2019. three March 31, 2020 2019, $198,000 no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2020 2019 Three Months Ended March 31, 2020 2019 North America $ 688 $ 1,792 Asia Pacific 597 967 Europe and Middle East 5 246 Latin America 14 - Other - 7 Total $ 1,304 $ 3,012 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. |
Equity Method Investments [Policy Text Block] | Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2020 2019. |
Standard Product Warranty, Policy [Policy Text Block] | Product Warranty The Company’s products sold to customers are generally subject to warranties between one three not |
Share-based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2020 2019, |
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Three Months Ended March 31, 2020 2019 Series B convertible preferred stock 32,667 (a) - Warrants to purchase common stock 23,665,905 6,408 Stock options to purchase common stock 10,432,654 55,864 Restricted common stock awards 2,620 4,176 (a) Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1 653.59 $1,000 $1.53 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not not no We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] | March 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 25 $ 108 $ (83 ) Total $ 25 $ 108 $ (83 ) |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended March 31, 2020 2019 North America $ 688 $ 1,792 Asia Pacific 597 967 Europe and Middle East 5 246 Latin America 14 - Other - 7 Total $ 1,304 $ 3,012 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended March 31, 2020 2019 Series B convertible preferred stock 32,667 (a) - Warrants to purchase common stock 23,665,905 6,408 Stock options to purchase common stock 10,432,654 55,864 Restricted common stock awards 2,620 4,176 |
Note 5 - Accrued Liabilities (T
Note 5 - Accrued Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | March 31, December 31, 2020 2019 Accrued payroll and other related expenses $ 719 $ 839 Deferred revenue - subscription rental program 703 662 Current operating lease liabilities 278 268 Accrued professional fees 224 592 Accrued bonuses 215 726 Accrued sales commission 60 281 Accrued inventory - 474 Accrued interest - 440 Other accruals 124 416 Total accrued liabilities $ 2,323 $ 4,698 |
Note 6 - Note Payable (Tables)
Note 6 - Note Payable (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Year Ending December 31, 2020 (remaining 9 months) $ - 2021 - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,871 ) Present value of obligations 4,121 Less: Unamortized debt discount (11 ) Note payable, noncurrent portion $ 4,110 |
Note 7 - Leases (Tables)
Note 7 - Leases (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Lessee, Lease Assets and Liabilities [Table Text Block] | March 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 332 $ 395 Liabilities: Current operating lease liabilities $ 278 $ 268 Noncurrent operating lease liabilities 59 132 $ 337 $ 400 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending December 31, 2020 (remaining 9 months) $ 228 2021 137 Total lease payments 365 Less: Amount representing interest (28 ) Present value of lease liabilities $ 337 |
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] | Year Ending December 31, 2020 (remaining 9 months) $ 660 2021 43 Thereafter - Total $ 703 |
Note 10 - Common Stock (Tables)
Note 10 - Common Stock (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 November 2019 Common Shares November 26, 2020 $ 1.55 6,393,113 November 2019 Common Shares November 26, 2024 $ 1.55 7,373,880 November 2019 Common Shares November 26, 2024 $ 1.84 9,893,776 23,665,905 |
Note 11 - Summary of Stock Op_2
Note 11 - Summary of Stock Options (Tables) | 3 Months Ended |
Mar. 31, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Three Months Ended March 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 10,087,678 $ 2.22 9.9 $ 3,928,715 Options granted 468,000 $ 0.88 Options exercised - Options canceled (123,024 ) $ 20.25 Options outstanding, end of period 10,432,654 $ 1.95 9.7 $ - Vested and exercisable and expected to vest, end of period 9,404,561 $ 2.04 9.7 $ - Vested and exercisable, end of period 833,785 $ 9.63 9.6 $ - |
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2020 Price Term (Years) March 31, 2020 Price $0.69 - $0.89 10,238,979 $ 0.86 9.7 813,153 $ 0.87 $1.09 - $1.36 155,000 $ 1.26 9.9 - $ - $38.00 - $58.00 1,600 $ 55.81 9.2 - $ - $100.00 - $197.00 20,352 $ 141.85 8.6 9,174 $ 147.74 $202.00 - $283.00 743 $ 251.21 7.6 392 $ 254.90 $311.00 - $382.00 2,625 $ 344.68 8.4 1,238 $ 345.28 $430.00 - $497.00 6,707 $ 454.33 7.3 4,281 $ 455.78 $501.00 - $567.00 3,215 $ 537.49 7.1 2,432 $ 536.76 $600.00 - $661.00 1,392 $ 602.19 5.8 1,375 $ 601.46 $700.00 - $792.00 1,937 $ 767.72 6.6 1,636 $ 767.47 $992.00 - $992.00 104 $ 992.00 2.8 104 $ 992.00 Total: 10,432,654 $ 1.95 9.7 833,785 $ 9.63 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 0.45% 2.53% Dividend yield 0% 0% Three Months Ended March 31, 2020 2019 Expected term (in years) 5 5 Average volatility 73% 73% Risk-free interest rate 1.39% 2.49% Dividend yield 0% 0% |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended March 31, 2020 2019 Cost of revenue $ 60 $ 32 Research and development 87 40 Selling, general and administrative 564 424 Total 710 $ 496 |
2017 Employee Stock Purchase Plan [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] | Three Months Ended March 31, 2020 2019 Expected term (in years) 0.25 0.25 Average volatility 124% 74% Risk-free interest rate 1.54% 2.45% Dividend yield 0% 0% |
Note 1 - The Company and Basi_2
Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($) | Nov. 26, 2019 | Nov. 12, 2019 | Aug. 16, 2019 | Feb. 29, 2020 | Jan. 31, 2020 | Dec. 31, 2019 | Nov. 30, 2019 | Aug. 31, 2019 | Mar. 31, 2020 | Sep. 30, 2019 | Mar. 31, 2019 | Nov. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | ||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,665,905 | |||||||||||||||
Proceeds from Warrant Exercises | $ 1,661,000 | |||||||||||||||
Retained Earnings (Accumulated Deficit), Ending Balance | $ (197,911,000) | [1] | (204,221,000) | $ (197,911,000) | [1] | |||||||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 13,308,000 | [1] | 9,042,000 | 17,821,000 | $ 13,308,000 | [1] | $ 29,523,000 | |||||||||
Working Capital | 12,399,000 | |||||||||||||||
Net Cash Provided by (Used in) Operating Activities, Total | $ (5,736,000) | $ (11,558,000) | ||||||||||||||
Conversion of Term Loan with CRG Into Stock and Warrants [Member] | ||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 28,981,000 | |||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 31,300,000 | |||||||||||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | ||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | 31,300 | ||||||||||||||
Series A Convertible Preferred Stock Into Common Stock [Member] | ||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 669,022 | 1,183,151 | 3,021,237 | 600,000 | ||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member] | ||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 1.53 | |||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member] | ||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 1.836 | |||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | 1 | |||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 1,852,173 | [2] | 0 | 1,852,173 | [2] | |||||||||||
Series A Convertible Preferred Stock [Member] | ||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | |||||||||||||||
Series A Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | $ 1.55 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 7,419,353 | 6,393,113 | 7,419,353 | |||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 1,026,240 | |||||||||||||||
Proceeds from Warrant Exercises | $ 1,591,000 | |||||||||||||||
Series B Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | $ 1.55 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 7,419,353 | 7,373,880 | 7,419,353 | |||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 45,473 | |||||||||||||||
Proceeds from Warrant Exercises | $ 70,000 | |||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.84 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 9,893,776 | 9,893,776 | 9,893,776 | |||||||||||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | |||||||||||||||
Class A Units [Member] | Series A Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||
Class A Units [Member] | Series B Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||
Class B Units [Member] | Series A Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||
Class B Units [Member] | Series B Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||
Common Stock [Member] | Series A Warrants [Member] | ||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 1,026,240 | |||||||||||||||
Common Stock [Member] | Series B Warrants [Member] | ||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 45,473 | |||||||||||||||
November 2019 Offering [Member] | ||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 11,500,000 | |||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 9,922,000 | |||||||||||||||
November 2019 Offering [Member] | Series A Preferred Stock [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 5,473,410 | |||||||||||||||
November 2019 Offering [Member] | Class A Units [Member] | ||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||
Common Shares Per Unit (in shares) | 1 | 1 | ||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | ||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.55 | $ 1.55 | ||||||||||||||
Series A Convertible Preferred Stock Per Unit (in shares) | 1 | 1 | ||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member] | ||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | ||||||||||||||
November 2019 Offering [Member] | Common Stock [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,945,943 | 1,945,943 | ||||||||||||||
August 2019 ATM Facility [Member] | ||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 6,322,000 | $ 6,322,000 | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,004,171 | 1,004,171 | ||||||||||||||
Aggregate Offering Price | $ 6,760,000 | $ 6,760,000 | ||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | |||||||||||||||
November 2017 ATM Facility [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | 0 | ||||||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. | |||||||||||||||
[2] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Sep. 18, 2019USD ($) | Mar. 31, 2020USD ($)$ / sharesshares | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($)$ / sharesshares | Nov. 30, 2019shares | |
Payments for Fractional Shares of Reverse Stock Split | $ 6,000 | |||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | [1] | |||
Common Stock, Shares Authorized (in shares) | shares | 75,000,000 | 75,000,000 | [1] | |||
Number of Financial Institutions | 1 | |||||
Accounts Receivable, Allowance for Credit Loss, Ending Balance | $ 481,000 | $ 407,000 | ||||
Accounts Receivable, Allowance for Credit Loss, Writeoff | 0 | $ 0 | ||||
Deferred Income | 703,000 | 662,000 | ||||
Contract with Customer, Liability, Revenue Recognized | 297,000 | |||||
Contract with Customer, Asset, after Allowance for Credit Loss, Total | 0 | 0 | ||||
Contract with Customer, Liability, Total | 25,000 | 108,000 | ||||
Capitalized Contract Cost, Net, Total | 211,000 | 337,000 | ||||
Capitalized Contract Cost, Impairment Loss | 0 | 0 | ||||
Capitalized Contract Cost, Amortization | 198,000 | 0 | ||||
Equity Method Investment, Other than Temporary Impairment | $ 0 | $ 0 | ||||
Series A Preferred Stock [Member] | ||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares | 1 | 1 | ||||
Series B Preferred Stock [Member] | ||||||
Conversion of Stock Exchange Ratio | 653.59 | |||||
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares | $ 1,000 | |||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | |||||
Minimum [Member] | ||||||
Warranty Period (Year) | 1 year | |||||
Maximum [Member] | ||||||
Warranty Period (Year) | 3 years | |||||
Marketing Programs [Member] | ||||||
Contract with Customer, Liability, Revenue Recognized | $ 83,000 | |||||
Contract with Customer, Liability, Total | $ 25,000 | $ 108,000 | ||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | ||||||
Concentration Risk, Number of Customers | 1 | 3 | ||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] | ||||||
Concentration Risk, Percentage | 48.00% | |||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Three Customers [Member] | ||||||
Concentration Risk, Percentage | 42.00% | |||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | ||||||
Concentration Risk, Number of Customers | 2 | 2 | ||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member] | ||||||
Concentration Risk, Percentage | 49.00% | 49.00% | ||||
Reverse Stock Split [Member] | ||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 100 | |||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2020 | Dec. 31, 2019 | |
Customer contract liabilities | $ 25,000 | $ 108,000 |
Change in customer contract liabilities | (83,000) | |
Marketing Programs [Member] | ||
Customer contract liabilities | 25,000 | $ 108,000 |
Change in customer contract liabilities | $ (83,000) |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Revenue | $ 1,304 | $ 3,012 |
North America [Member] | ||
Revenue | 688 | 1,792 |
Asia Pacific [Member] | ||
Revenue | 597 | 967 |
Europe And Middle East [Member] | ||
Revenue | 5 | 246 |
Latin America [Member] | ||
Revenue | 14 | |
Other [Member] | ||
Revenue | $ 7 |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares | 3 Months Ended | ||
Mar. 31, 2020 | Mar. 31, 2019 | ||
Series B Convertible Preferred Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 32,667 | [1] | |
Common Stock Warrants [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 23,665,905 | 6,408 | |
Share-based Payment Arrangement, Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 10,432,654 | 55,864 | |
Restricted Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 2,620 | 4,176 | |
[1] | Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-653.59 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $1.53 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company’s stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares. |
Note 4 - Investment in Limite_2
Note 4 - Investment in Limited Liability Company (Details Textual) | Aug. 08, 2017USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Income (Loss) from Equity Method Investments, Total | $ (182,000) | $ (125,000) | |||
InControl Medical [Member] | |||||
Equity Method Investment, Ownership Percentage | 7.00% | 7.00% | |||
Income (Loss) from Equity Method Investments, Total | $ 182,000 | $ 125,000 | |||
InControl Medical [Member] | Membership Unit Subscription Agreement [Member] | |||||
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased | 120 | 300 | 4,920 | ||
Unrecorded Unconditional Purchase Obligation, Purchases | $ 10,000 | $ 27,000 | |||
Payments for Purchase of Products | 10,000 | $ 27,000 | |||
Accounts Payable, Related Parties, Current | $ 0 | $ 0 | $ 0 | ||
Payments to Acquire Equity Method Investments | $ 2,500,000 |
Note 5 - Accrued Liabilities -
Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 | |
Accrued payroll and other related expenses | $ 719 | $ 839 | |
Deferred revenue - subscription rental program | 703 | 662 | |
Accrued professional fees | 224 | 592 | |
Accrued bonuses | 215 | 726 | |
Accrued sales commission | 60 | 281 | |
Accrued inventory | 474 | ||
Accrued interest | 440 | ||
Other accruals | 124 | 416 | |
Total accrued liabilities | 2,323 | 4,698 | [1] |
Accrued Liabilities [Member] | |||
Current operating lease liabilities | $ 278 | $ 268 | |
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 6 - Note Payable (Details
Note 6 - Note Payable (Details Textual) | Nov. 26, 2019USD ($)$ / sharesshares | Nov. 12, 2019USD ($)$ / sharesshares | Dec. 29, 2017USD ($) | May 22, 2017USD ($)$ / sharesshares | Mar. 31, 2020USD ($)$ / sharesshares | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($) | |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 23,665,905 | |||||||
Notes Payable, Noncurrent, Total | $ 4,110,000 | $ 3,983,000 | [1] | |||||
Share Price (in dollars per share) | $ / shares | $ 0.869 | |||||||
Gains (Losses) on Restructuring of Debt | $ (6,705,000) | |||||||
Series B Preferred Stock [Member] | ||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | |||||||
Preferred Stock, Fair Value, Per Share (in dollars per share) | $ / shares | $ 1,023.23 | |||||||
Convertible Preferred Stock, Fair Value | $ 32,027,000 | |||||||
Series B Preferred Stock [Member] | Measurement Input, Option Volatility [Member] | ||||||||
Convertible Preferred Stock, Measurement Input | 73 | |||||||
Series B Preferred Stock [Member] | Measurement Input, Expected Term [Member] | ||||||||
Convertible Preferred Stock, Measurement Input | 2 | |||||||
Series B Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||
Convertible Preferred Stock, Measurement Input | 1.58 | |||||||
Minimum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member] | ||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | |||||||
Maximum [Member] | Series B Convertible Preferred Stock Into Common Stock [Member] | ||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.836 | |||||||
Conversion of Term Loan with CRG Into Stock and Warrants [Member] | ||||||||
Debt Conversion, Original Debt, Amount | $ 28,981,000 | |||||||
Debt Conversion, Converted Instrument, Amount | $ 31,300,000 | |||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | ||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares | 31,300 | 31,300 | ||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | ||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 2,220 | 2,220 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 950 | $ 950 | ||||||
Warrants and Rights Outstanding | $ 940,000 | |||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares | 9,893,776 | 9,893,776 | 9,893,776 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.84 | |||||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | |||||||
Warrants and Rights Outstanding | $ 3,502,000 | $ 3,502,000 | ||||||
The 2017 Loan Agreement [Member] | CRG LP [Member] | ||||||||
Debt Instrument, Face Amount | 20,000,000 | |||||||
Debt Agreement, Covenant, Additional Funding | 10,000,000 | |||||||
Debt Agreement, Maximum Borrowing Capacity | $ 30,000,000 | |||||||
Proceeds from Lines of Credit, Total | $ 10,000,000 | |||||||
Debt Instrument, Term (Year) | 6 years | |||||||
Debt instrument, Interest Only Payment, Period (Year) | 4 years | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||||
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period | 4.00% | |||||||
Paid-in-Kind Interest | $ 126,000 | $ 318,000 | ||||||
Debt Instrument, Prepayment Fee, Percentage | 5.00% | |||||||
Debt Instrument, Covenant, Cash and Cash Equivalents | $ 2,000,000 | |||||||
Debt Instrument, Back-end Facility Fee Percentage of Principal | 25.00% | 5.00% | ||||||
Notes Payable, Noncurrent, Total | $ 4,110,000 | $ 3,983,000 | ||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 6 - Note Payable - Summary
Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) | Mar. 31, 2020 | Dec. 31, 2019 | [1] |
2020 (remaining 9 months) | |||
2021 | |||
2022 | |||
2023 | 5,992,000 | ||
Total payments | 5,992,000 | ||
Less: Amount representing interest | (1,871,000) | ||
Present value of obligations | 4,121,000 | ||
Less: Unamortized debt discount | (11,000) | ||
Note payable, noncurrent portion | $ 4,110,000 | $ 3,983,000 | |
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 7 - Leases (Details Textua
Note 7 - Leases (Details Textual) | 1 Months Ended | 3 Months Ended | ||||
Sep. 30, 2018USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2019USD ($) | Feb. 01, 2017USD ($)ft² | ||
Operating Leases, Rent Expense, Total | $ 76,000 | $ 75,000 | ||||
Operating Lease, Weighted Average Remaining Lease Term (Month) | 1 year 60 days | |||||
Operating Lease, Weighted Average Discount Rate, Percent | 12.50% | |||||
Operating Lease, Property Plant and Equipment, Amount | $ 2,973,000 | $ 3,046,000 | [1] | |||
Lessor, Operating Lease, Depreciation on Leased Assets | 323,000 | $ 311,000 | ||||
Assets Leased to Others [Member] | ||||||
Operating Lease, Property Plant and Equipment, Amount | 1,163,000 | |||||
Lessor, Operating Lease, Depreciation on Leased Assets | $ 113,000 | |||||
Sublease Agreement for Relocation of Headquarters [Member] | ||||||
Area of Real Estate Property (Square Foot) | ft² | 12,400 | |||||
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | 20.5 | |||||
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | 21.12 | |||||
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | 21.75 | |||||
Security Deposit | $ 22,000 | |||||
Operating Leases, Allowance for Certain Improvements | $ 88,000 | |||||
Noncancelable Operating Lease Agreement for Office Equipment [Member] | ||||||
Lessee, Operating Lease, Term of Contract (Month) | 3 years | |||||
Operating Leases, Monthly Payment | $ 3,000 | |||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 7 - Leases - Lease Assets
Note 7 - Leases - Lease Assets and Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
Operating lease right-of-use assets | $ 332 | $ 395 |
Accrued Liabilities [Member] | ||
Current operating lease liabilities | 278 | 268 |
Other Noncurrent Liabilities [Member] | ||
Noncurrent operating lease liabilities | 59 | 132 |
Accrued Liabilities and Other Noncurrent Liabilities [Member] | ||
Operating Lease, Liability, Total | $ 337 | $ 400 |
Note 7 - Leases - Maturity of O
Note 7 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2020 | Dec. 31, 2019 |
2020 (remaining 9 months) | $ 228 | |
2021 | 137 | |
Total lease payments | 365 | |
Less: Amount representing interest | (28) | |
Accrued Liabilities and Other Noncurrent Liabilities [Member] | ||
Present value of lease liabilities | $ 337 | $ 400 |
Note 7 - Leases - Minimum Futur
Note 7 - Leases - Minimum Future Rentals (Details) $ in Thousands | Mar. 31, 2020USD ($) |
2020 (remaining 9 months) | $ 660 |
2021 | 43 |
Thereafter | |
Total | $ 703 |
Note 9 - Preferred Stock (Detai
Note 9 - Preferred Stock (Details Textual) - USD ($) | Nov. 26, 2019 | Nov. 12, 2019 | Feb. 29, 2020 | Jan. 31, 2020 | Dec. 31, 2019 | Nov. 30, 2019 | Mar. 31, 2020 | Dec. 31, 2019 | ||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,665,905 | |||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 9,893,776 | 9,893,776 | 9,893,776 | |||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | ||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | 31,300 | ||||||||
Series A Convertible Preferred Stock Into Common Stock [Member] | ||||||||||
Conversion of Stock, Shares Converted (in shares) | 669,022 | 1,183,151 | 3,021,237 | 600,000 | ||||||
Series A Preferred Stock [Member] | ||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | ||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 1,852,173 | [1] | 0 | 1,852,173 | [1] | |||||
Series A Convertible Preferred Stock [Member] | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | |||||||||
Series B Preferred Stock [Member] | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 31,678 | [1] | 32,667 | 31,678 | [1] | |||||
Preferred Stock, Dividend Rate, Percentage | 12.50% | |||||||||
Preferred Stock Dividends, Shares (in shares) | 989 | 378 | ||||||||
Dividends, Preferred Stock, Cash | $ 1,000 | $ 2,400 | ||||||||
Preferred Stock, Fair Value, Per Share (in dollars per share) | $ 1,023.23 | |||||||||
Convertible Preferred Stock, Fair Value | $ 32,027,000 | |||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 31,300 | |||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2019 has been derived from the audited consolidated financial statements as of that date. |
Note 10 - Common Stock (Details
Note 10 - Common Stock (Details Textual) | Aug. 16, 2019USD ($) | Mar. 31, 2020USD ($)$ / sharesshares | Feb. 29, 2020USD ($)shares | Jan. 31, 2020shares | Dec. 31, 2019USD ($)shares | Nov. 30, 2019USD ($)$ / sharesshares | Oct. 31, 2019USD ($) | Aug. 31, 2019USD ($) | Mar. 31, 2019USD ($) | Mar. 31, 2020USD ($)$ / sharesshares | Sep. 30, 2019USD ($)shares | Mar. 31, 2019USD ($)shares | Nov. 30, 2019USD ($)$ / sharesshares | Dec. 31, 2019USD ($)shares | Nov. 26, 2019USD ($)shares | Nov. 12, 2019USD ($)$ / sharesshares | May 22, 2017USD ($)yr$ / sharesshares |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,665,905 | 23,665,905 | |||||||||||||||
Proceeds from Warrant Exercises | $ | $ 1,661,000 | ||||||||||||||||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ | 25,000 | ||||||||||||||||
Amortization of Debt Discount (Premium) | $ | 1,000 | $ 83,000 | |||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ | $ 11,000 | $ 11,000 | |||||||||||||||
Class of Warrants or Rights, Exercises in Period (in shares) | 0 | 0 | |||||||||||||||
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares) | 0 | 0 | |||||||||||||||
Share-based Payment Arrangement, Expense | $ | $ 710,000 | $ 496,000 | |||||||||||||||
Class of Warrant or Right, Issued During Period (in shares) | 0 | 0 | |||||||||||||||
The 2017 Loan Agreement [Member] | |||||||||||||||||
Debt Issuance Costs, Net, Total | $ | 790,000 | $ 790,000 | |||||||||||||||
Restricted Stock [Member] | |||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ | 28,313 | $ 30,675 | $ 7,740 | $ 274 | |||||||||||||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ | $ 24,000 | $ 25,000 | $ 25,000 | $ 25,000 | |||||||||||||
Series A Convertible Preferred Stock Into Common Stock [Member] | |||||||||||||||||
Conversion of Stock, Shares Converted (in shares) | 669,022 | 1,183,151 | 3,021,237 | 600,000 | |||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member] | |||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | ||||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member] | |||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.836 | ||||||||||||||||
Series A Preferred Stock [Member] | |||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | 1 | 1 | |||||||||||||
Series B Preferred Stock [Member] | |||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 1.53 | $ 1.53 | |||||||||||||||
Series A Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | $ 1.55 | $ 1.55 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,393,113 | 7,419,353 | 6,393,113 | 7,419,353 | |||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 1,026,240 | ||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 1,591,000 | ||||||||||||||||
Warrants and Rights Outstanding | $ | $ 1,210,000 | $ 1,210,000 | |||||||||||||||
Series A Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 | |||||||||||||||
Series A Warrants [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 91.1 | 91.1 | |||||||||||||||
Series A Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.59 | 1.59 | |||||||||||||||
Series B Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | $ 1.55 | $ 1.55 | |||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 7,373,880 | 7,419,353 | 7,373,880 | 7,419,353 | |||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 45,473 | ||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 70,000 | ||||||||||||||||
Warrants and Rights Outstanding | $ | $ 2,871,000 | $ 2,871,000 | |||||||||||||||
Series B Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 | |||||||||||||||
Series B Warrants [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 68.8 | 68.8 | |||||||||||||||
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.58 | 1.58 | |||||||||||||||
Series A and Series B Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | |||||||||||||||
Warrants and Rights Outstanding | $ | $ 4,081,000 | $ 4,081,000 | |||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.84 | $ 1.84 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 9,893,776 | 9,893,776 | 9,893,776 | 9,893,776 | |||||||||||||
Warrants and Rights Outstanding | $ | $ 3,502,000 | $ 3,502,000 | |||||||||||||||
Class of Warrants or Rights, Outstanding, Percentage of Common Stock | 15.00% | ||||||||||||||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | ||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | ||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 68.8 | ||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.58 | ||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | |||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 950 | $ 950 | $ 950 | ||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,220 | 2,220 | 2,220 | ||||||||||||||
Warrants and Rights Outstanding | $ | $ 940,000 | ||||||||||||||||
Share-based Payment Arrangement, Expense | $ | $ 0 | $ 0 | |||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | ||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.551 | ||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.0225 | ||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member] | |||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | yr | 10 | ||||||||||||||||
Class A Units [Member] | Series A Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | |||||||||||||||
Class A Units [Member] | Series B Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | |||||||||||||||
Class B Units [Member] | Series A Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | |||||||||||||||
Class B Units [Member] | Series B Warrants [Member] | |||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | |||||||||||||||
Common Stock [Member] | |||||||||||||||||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ | |||||||||||||||||
Common Stock [Member] | Series A Warrants [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 1,026,240 | ||||||||||||||||
Common Stock [Member] | Series B Warrants [Member] | |||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 45,473 | ||||||||||||||||
November 2019 Offering [Member] | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 11,500,000 | ||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ | $ 9,922,000 | ||||||||||||||||
November 2019 Offering [Member] | Series A Preferred Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 5,473,410 | ||||||||||||||||
November 2019 Offering [Member] | Series B Preferred Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 5,473,410 | ||||||||||||||||
November 2019 Offering [Member] | Class A Units [Member] | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | |||||||||||||||
Common Shares Per Unit (in shares) | 1 | 1 | |||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | |||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 1.55 | $ 1.55 | |||||||||||||||
Series A Convertible Preferred Stock Per Unit (in shares) | 1 | 1 | |||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member] | |||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | |||||||||||||||
November 2019 Offering [Member] | Common Stock [Member] | |||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,945,943 | 1,945,943 | |||||||||||||||
August 2019 ATM Facility [Member] | |||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ | $ 6,322,000 | $ 6,322,000 | |||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,004,171 | 1,004,171 | |||||||||||||||
Aggregate Offering Price | $ | $ 6,760,000 | $ 6,760,000 |
Note 10 - Common Stock - Summar
Note 10 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares | 3 Months Ended | ||||
Mar. 31, 2020 | Nov. 30, 2019 | Nov. 26, 2019 | Nov. 12, 2019 | May 22, 2017 | |
Shares Outstanding Under Warrants (in shares) | 23,665,905 | ||||
Employee Performance Bonus Warrants, February 2015 Issuance [Member] | |||||
Expiration Date | Feb. 17, 2025 | ||||
Exercise Price (in dollars per share) | $ 400 | ||||
Shares Outstanding Under Warrants (in shares) | 754 | ||||
Contractor Warrants, March 2015 Issuance [Member] | |||||
Expiration Date | Mar. 26, 2025 | ||||
Exercise Price (in dollars per share) | $ 272 | ||||
Shares Outstanding Under Warrants (in shares) | 14 | ||||
Contractor Warrants, May 2015 Issuance [Member] | |||||
Expiration Date | May 12, 2025 | ||||
Exercise Price (in dollars per share) | $ 424 | ||||
Shares Outstanding Under Warrants (in shares) | 362 | ||||
May 2015 Issuance Second Contractor [Member] | |||||
Expiration Date | May 17, 2020 | ||||
Exercise Price (in dollars per share) | $ 424 | ||||
Shares Outstanding Under Warrants (in shares) | 215 | ||||
Performance Bonus Warrants, December 2015 Issuance [Member] | |||||
Expiration Date | Dec. 16, 2025 | ||||
Exercise Price (in dollars per share) | $ 560 | ||||
Shares Outstanding Under Warrants (in shares) | 267 | ||||
Distributor Warrants, April 2016 Issuance [Member] | |||||
Expiration Date | Apr. 1, 2026 | ||||
Exercise Price (in dollars per share) | $ 608 | ||||
Shares Outstanding Under Warrants (in shares) | 250 | ||||
Contractor Warrants, May 2016 Issuance [Member] | |||||
Expiration Date | May 11, 2021 | ||||
Exercise Price (in dollars per share) | $ 774 | ||||
Shares Outstanding Under Warrants (in shares) | 50 | ||||
June 2016 Issuance Related to 2016 Loan Agreement [Member] | |||||
Expiration Date | Jun. 20, 2026 | ||||
Exercise Price (in dollars per share) | $ 498 | ||||
Shares Outstanding Under Warrants (in shares) | 1,004 | ||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | |||||
Expiration Date | May 25, 2027 | ||||
Exercise Price (in dollars per share) | $ 950 | $ 950 | |||
Shares Outstanding Under Warrants (in shares) | 2,220 | 2,220 | |||
Series A Warrants [Member] | |||||
Expiration Date | Nov. 26, 2020 | ||||
Exercise Price (in dollars per share) | $ 1.55 | $ 1.55 | |||
Shares Outstanding Under Warrants (in shares) | 6,393,113 | 7,419,353 | |||
Series B Warrants [Member] | |||||
Expiration Date | Nov. 26, 2024 | ||||
Exercise Price (in dollars per share) | $ 1.55 | $ 1.55 | |||
Shares Outstanding Under Warrants (in shares) | 7,373,880 | 7,419,353 | |||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | |||||
Expiration Date | Nov. 26, 2024 | ||||
Exercise Price (in dollars per share) | $ 1.84 | ||||
Shares Outstanding Under Warrants (in shares) | 9,893,776 | 9,893,776 | 9,893,776 |
Note 11 - Summary of Stock Op_3
Note 11 - Summary of Stock Options (Details Textual) - USD ($) | Mar. 31, 2020 | Jan. 01, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jun. 28, 2019 | Mar. 29, 2019 | Jul. 31, 2019 | Jun. 30, 2019 | Apr. 30, 2019 | Jan. 31, 2019 | Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | Nov. 26, 2019 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 10,432,654 | 10,087,678 | 10,432,654 | 10,087,678 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 1.95 | $ 2.22 | $ 1.95 | $ 2.22 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 9 years 255 days | 9 years 328 days | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 468,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | ||||||||||||
Director [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 525 | |||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) | 378 | 525 | ||||||||||||
Consultant [Member] | ||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) | 250 | |||||||||||||
Nonemployees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | ||||||||||||
Restricted Stock [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 2,620 | 2,620 | ||||||||||||
Restricted Stock [Member] | Director [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 38.08 | $ 91 | ||||||||||||
Share-based Payment Arrangement, Option [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 7,341,000 | $ 7,341,000 | ||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 3 years 36 days | |||||||||||||
The 2006 Stock Option Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 104 | 104 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 0 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 992 | $ 992 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 2 years 292 days | |||||||||||||
The 2013 Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 10,432,550 | 10,432,550 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 4,093,287 | 4,093,287 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 1.94 | $ 1.94 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 9 years 255 days | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 2,639,926 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 14,512,457 | 11,872,531 | ||||||||||||
The 2013 Plan [Member] | Employees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 368,000 | 21,175 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 0.75 | $ 123.66 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | 0 | ||||||||||||
The 2013 Plan [Member] | Nonemployees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 100,000 | 275 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 1.36 | $ 121.82 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | 0 | ||||||||||||
The 2013 Plan [Member] | Restricted Stock [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 3,625 | 0 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) | 0 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 0 | |||||||||||||
2017 Employee Stock Purchase Plan [Member] | ||||||||||||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | 320 | 300 | 200 | 602 | 429 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 0.59 | $ 1.07 | $ 3.75 | $ 32.30 | $ 79.88 | $ 0.59 | $ 1.07 | |||||||
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares) | 772 | 772 | ||||||||||||
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased (in dollars per share) | $ 0.43 | $ 33 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% |
Note 11 - Summary of Stock Op_4
Note 11 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Dec. 31, 2019 | |
Options outstanding, beginning of period (in shares) | 10,087,678 | |
Options outstanding, weighted average exercise price (in dollars per share) | $ 2.22 | |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 255 days | 9 years 328 days |
Options outstanding, aggregate intrinsic value | $ 3,928,715 | |
Options granted (in shares) | 468,000 | |
Options granted, weighted average exercise price (in dollars per share) | $ 0.88 | |
Options exercised (in shares) | ||
Options exercised, weighted average exercise price (in dollars per share) | ||
Options canceled (in shares) | (123,024) | |
Options canceled, weighted average exercise price (in dollars per share) | $ 20.25 | |
Options outstanding, end of period (in shares) | 10,432,654 | 10,087,678 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 1.95 | $ 2.22 |
Vested and exercisable and expected to vest, end of period (in shares) | 9,404,561 | |
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share) | $ 2.04 | |
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year) | 9 years 255 days | |
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value | ||
Vested and exercisable, end of period (in shares) | 833,785 | |
Vested and exercisable, end of period, weighted average exercise price (in dollars per share) | $ 9.63 | |
Vested and exercisable, end of period, weighted average remaining contractual term (Year) | 9 years 219 days | |
Vested and exercisable, end of period, aggregate intrinsic value |
Note 11 - Summary of Stock Op_5
Note 11 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details) | 3 Months Ended |
Mar. 31, 2020$ / sharesshares | |
Options outstanding, number (in shares) | shares | 10,432,654 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 1.95 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 255 days |
Options exercisable, number exercisable (in shares) | shares | 833,785 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 9.63 |
Range One [Member] | |
Exercise price range, lower limit (in dollars per share) | 0.69 |
Exercise price range, upper limit (in dollars per share) | $ 0.89 |
Options outstanding, number (in shares) | shares | 10,238,979 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 0.86 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 255 days |
Options exercisable, number exercisable (in shares) | shares | 813,153 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 0.87 |
Range Two [Member] | |
Exercise price range, lower limit (in dollars per share) | 1.09 |
Exercise price range, upper limit (in dollars per share) | $ 1.36 |
Options outstanding, number (in shares) | shares | 155,000 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 1.26 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 328 days |
Options exercisable, number exercisable (in shares) | shares | |
Options exercisable, weighted average exercise price (in dollars per share) | |
Range Three [Member] | |
Exercise price range, lower limit (in dollars per share) | 38 |
Exercise price range, upper limit (in dollars per share) | $ 58 |
Options outstanding, number (in shares) | shares | 1,600 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 55.81 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 73 days |
Options exercisable, number exercisable (in shares) | shares | |
Options exercisable, weighted average exercise price (in dollars per share) | |
Range Four [Member] | |
Exercise price range, lower limit (in dollars per share) | 100 |
Exercise price range, upper limit (in dollars per share) | $ 197 |
Options outstanding, number (in shares) | shares | 20,352 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 141.85 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 219 days |
Options exercisable, number exercisable (in shares) | shares | 9,174 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 147.74 |
Range Five [Member] | |
Exercise price range, lower limit (in dollars per share) | 202 |
Exercise price range, upper limit (in dollars per share) | $ 283 |
Options outstanding, number (in shares) | shares | 743 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 251.21 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 219 days |
Options exercisable, number exercisable (in shares) | shares | 392 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 254.90 |
Range Six [Member] | |
Exercise price range, lower limit (in dollars per share) | 311 |
Exercise price range, upper limit (in dollars per share) | $ 382 |
Options outstanding, number (in shares) | shares | 2,625 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 344.68 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 146 days |
Options exercisable, number exercisable (in shares) | shares | 1,238 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 345.28 |
Range Seven [Member] | |
Exercise price range, lower limit (in dollars per share) | 430 |
Exercise price range, upper limit (in dollars per share) | $ 497 |
Options outstanding, number (in shares) | shares | 6,707 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 454.33 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 109 days |
Options exercisable, number exercisable (in shares) | shares | 4,281 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 455.78 |
Range Eight [Member] | |
Exercise price range, lower limit (in dollars per share) | 501 |
Exercise price range, upper limit (in dollars per share) | $ 567 |
Options outstanding, number (in shares) | shares | 3,215 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 537.49 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 36 days |
Options exercisable, number exercisable (in shares) | shares | 2,432 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 536.76 |
Range Nine [Member] | |
Exercise price range, lower limit (in dollars per share) | 600 |
Exercise price range, upper limit (in dollars per share) | $ 661 |
Options outstanding, number (in shares) | shares | 1,392 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 602.19 |
Options outstanding, weighted average remaining contractual term (Year) | 5 years 292 days |
Options exercisable, number exercisable (in shares) | shares | 1,375 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 601.46 |
Range Ten [Member] | |
Exercise price range, lower limit (in dollars per share) | 700 |
Exercise price range, upper limit (in dollars per share) | $ 792 |
Options outstanding, number (in shares) | shares | 1,937 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 767.72 |
Options outstanding, weighted average remaining contractual term (Year) | 6 years 219 days |
Options exercisable, number exercisable (in shares) | shares | 1,636 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 767.47 |
Range Eleven [Member] | |
Exercise price range, lower limit (in dollars per share) | 992 |
Exercise price range, upper limit (in dollars per share) | $ 992 |
Options outstanding, number (in shares) | shares | 104 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 992 |
Options outstanding, weighted average remaining contractual term (Year) | 2 years 292 days |
Options exercisable, number exercisable (in shares) | shares | 104 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 992 |
Note 11 - Summary of Stock Op_6
Note 11 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Expected term (Year) | 5 years | 5 years |
Average volatility | 73.00% | 73.00% |
Risk-free interest rate | 0.45% | 2.53% |
Dividend yield | 0.00% | 0.00% |
2017 Employee Stock Purchase Plan [Member] | ||
Expected term (Year) | 91 days | 91 days |
Average volatility | 124.00% | 74.00% |
Risk-free interest rate | 1.54% | 2.45% |
Dividend yield | 0.00% | 0.00% |
Note 11 - Summary of Stock Op_7
Note 11 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details) | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Expected term (Year) | 5 years | 5 years |
Average volatility | 73.00% | 73.00% |
Risk-free interest rate | 0.45% | 2.53% |
Dividend yield | 0.00% | 0.00% |
Nonemployees [Member] | ||
Expected term (Year) | 5 years | 5 years |
Average volatility | 73.00% | 73.00% |
Risk-free interest rate | 1.39% | 2.49% |
Dividend yield | 0.00% | 0.00% |
Note 11 - Summary of Stock Op_8
Note 11 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | |
Stock-based compensation expense | $ 710 | $ 496 |
Cost of Sales [Member] | ||
Stock-based compensation expense | 60 | 32 |
Research and Development Expense [Member] | ||
Stock-based compensation expense | 87 | 40 |
Selling, General and Administrative Expenses [Member] | ||
Stock-based compensation expense | $ 564 | $ 424 |
Note 12 - Income Taxes (Details
Note 12 - Income Taxes (Details Textual) - USD ($) xbrli-pure in Thousands, $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2020 | Dec. 31, 2020 | |
Income Tax Expense (Benefit), Total | $ 0 | |
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% | |
Forecast [Member] | ||
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% |
Note 13 - Related Party Trans_2
Note 13 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($) | 3 Months Ended | 123 Months Ended | |
Mar. 31, 2020 | Mar. 31, 2019 | Dec. 31, 2019 | |
Stock Issued During Period, Shares, New Issues (in shares) | 375 | ||
Related Party Transaction, Amounts of Transaction | $ 282,000 | $ 1,489,000 | |
Accounts Payable, Related Parties, Current | $ 323,000 | $ 124,000 |
Note 14 - Restructuring Costs (
Note 14 - Restructuring Costs (Details Textual) | 1 Months Ended | 3 Months Ended | |
Jan. 31, 2019USD ($) | Mar. 31, 2020USD ($) | Mar. 31, 2019USD ($) | |
Restructuring and Related Cost, Number of Positions Eliminated | 40 | ||
Restructuring Charges, Total | $ 742,000 | $ 742,000 |
Note 15 - Subsequent Events (De
Note 15 - Subsequent Events (Details Textual) - USD ($) | Apr. 24, 2020 | Apr. 20, 2020 | Apr. 15, 2020 | Mar. 31, 2020 | Nov. 30, 2019 |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 23,665,905 | ||||
Series A and Series B Warrants [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | ||||
Series A Warrants [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 6,393,113 | 7,419,353 | |||
Warrants and Rights Outstanding, Term (Year) | 1 year | ||||
Series B Warrants [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | |||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 7,373,880 | 7,419,353 | |||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||
Subsequent Event [Member] | |||||
Proceeds from Paycheck Protection Program Under CARES Act | $ 1,343,400 | ||||
Subsequent Event [Member] | Series A and Series B Warrants [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.61 | ||||
Proceeds from Issuance of Warrants | $ 3,100,000 | ||||
Subsequent Event [Member] | Series A Warrants [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,820,584 | ||||
Subsequent Event [Member] | Series B Warrants [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 242,790 | ||||
Subsequent Event [Member] | Series A-2 Warrants [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 4,820,584 | ||||
Subsequent Event [Member] | Series B-2 Warrants [Member] | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 242,790 | ||||
Subsequent Event [Member] | Series A-2 and Series B-2 Warrants [Member] | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.6371 | ||||
Warrants and Rights Outstanding, Term (Year) | 5 years |